Adenosine A2a Receptor CLIA Kit

Catalog No. ABIN6201458

Product Details Adenosine A2a Receptor CLIA Kit

Target: Adenosine A2a Receptor (ADORA2A)

Reactivity: Human

Detection Method: Chemiluminescent

Method Type: Sandwich ELISA

Detection Range: 0.156 ng/mL - 10 ng/mL

Minimum Detection Limit: 0.156 ng/mL

Application: ELISA

Purpose: Human Adenosine A2a Receptor (ADORA2a) CLIA Kit is a Sandwich CLIA Kit for use with Tissue homogenates and other biological fluids.

Sample Type: Tissue Homogenate

Analytical Method: Quantitative

Sensitivity: < 0.06 ng/mL

Application Details

Application Notes:

Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5 % within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Standard Form: Lyophilized

Plate: Pre-coated

Restrictions: For Research Use only

Handling

Storage: 4 °C/-20 °C

Storage Comment: Upon receipt, store the kit according to the storage instruction in the kit's manual.

Expiry Date: 6 months

Target Details

Target: Adenosine A2a Receptor (ADORA2A)

Alternative Name: ADORA2A (ADORA2A Products)

Synonyms: ADORA2A CLIA Kit, adora2a.1 CLIA Kit, zgc:194773 CLIA Kit, A2aR CLIA Kit, ADORA2 CLIA Kit, RDC8 CLIA Kit, A2AAR CLIA Kit, AA2AR CLIA Kit, A2ar CLIA Kit, ADENO CLIA Kit, Adora2l1 CLIA Kit, adora2a.2 CLIA Kit, zgc:193802 CLIA Kit, zgc:193822 CLIA Kit, adenosine A2a receptor CLIA Kit, adenosine A2a receptor a CLIA Kit, adenosine A2a receptor L homeolog CLIA Kit, adenosine A2a receptor b CLIA Kit, ADORA2A CLIA Kit, Adora2a CLIA Kit, adora2aa CLIA Kit, adora2a.L CLIA Kit, adora2a CLIA Kit, adora2ab CLIA Kit

Pathways: Neurotrophin Signaling Pathway, cAMP Metabolic Process, Synaptic Membrane, Feeding Behaviour, Cancer Immune Checkpoints